PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib (Q40033522)
scientific article published on December 2007
Language:
(P31) (Q13442814)
(P50) (Q55130361)
(Q47451221)
(Q74766165)
(Q88721314)
(P304) 11924-11932
(P407) (Q1860)
(P433) 24
(P478) 67
(P577) Saturday, December 1, 2007
(P921) (Q415271)
(Q47912)
(P1433) (Q326097)
(P1476) "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib" (language: en)
(P2093) Jeffrey A Engelman
Kreshnik Zejnullahu
Christopher-Michael Gale
Eugene Lifshits
Andrea J Gonzales
Takeshi Shimamura
Feng Zhao
Patrick W Vincent
George N Naumov
James E Bradner
Irene W Althaus
Geoffrey I Shapiro
James M Nelson
Kwok-Kin Wong
other details
description scientific article published on December 2007

External Links